Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{205577,
        author = {Panga silas and k Archana},
        title = {FORMULATION AND EVALUATION OF LANDIOLOL HYDROCHLORIDE IMMEDIATE RELEASE TABLET},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {13},
        number = {1},
        pages = {7652-7668},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=205577},
        abstract = {Landiolol hydrochloride is a highly selective ultra-short acting beta-1 adrenergic receptor blocker, including some alpha-1 blocker effects. Thus, administered to patients who suffer with the conditions: congestive heart failure; hypertension; and in post-myocardial infarction, being such a high-line useful drug and also potent with dose as low as 3.25 mg being effective, a quick and effective delivery would be a crucial step in health management of patients with CHF and hypertension. Formulating and developing an Immediate-Release Tablet, which is as close in comparison to a standard marketed tablet is the aim of this study. The key factors in IR tablets are the dissolution profile and disintegration time. Super-disintegrates are polymers which aid in quickly disintegrating the tablets in body aiding in quicker release of drug. Polymers of different caliber were subjected to preformulation studies with drug to test the compatibility and among them Croscarmellose sodium, Microcrystalline cellulose and Povidone were included as the super-disintegrants. Ten different formulations were designed and developed, varying in composition of binders, diluents to develop a superior tablet formula, out of all the 10 formulations, F1 & F2 failed to meet pre compression evaluation studies and remaining 7 formulations were prepared using wet granulation process, showed fair amount of dissolution done as per USP standards in comparison to standard Landiolol HCL IR tablet Coreg-25. The disintegration and dissolution studies were carried in various buffers with 0.1N HCl being deemed the most suitable one, the assay was done using HPLC which led to the conclusion that F9 & F10, having larger amounts of super-disintegrants showed the best dissolution of 98.54% and 99.43% drug release within 45 mins. Both the formulations were subjected to stability studies under the ICH guidelines to further test the stability and were studied for 2 months showing no change in appearance, however the assay showed decrease in drug release to 98% but within the IP limits, showcasing that the formulated tablets were stable, effective and pharmaceutical equivalent to marketed product.},
        keywords = {Landiolol hydrochloride, Immediate-Release, Super-disintegrant, wet granulation, Assay, Dissolution, Stability studies.},
        month = {June},
        }